Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Mallinckrodt
Baxter
Accenture
Farmers Insurance
Healthtrust
US Army
McKesson
Boehringer Ingelheim

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,987,333

« Back to Dashboard

Title:Composition and method for treating neurological disease
Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Jasper, GA), Porter; Seth (San Carlos, CA), Meyerson; Laurence R. (Las Vegas, NV), Burkoth; Timothy S. (Lake Bluff, IL)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Filing Date:Aug 04, 2014
Application Number:14/451,262
Claims:1. An osmotic device comprising a core surrounded by a semipermeable membrane having an exit means there through wherein: a) the core comprises a mixture of (i) a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, (ii) an osmotically active component and (iii) at least one other excipient, b) the osmotic device further comprises an immediate release overcoat layer comprising the drug, c) the osmotic device comprises a total of 50 mg to 500 mg of the drug, and at least 50% of the total drug is provided in the core, and d) the osmotic device provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT provided by the same quantity of an immediate release form of the drug, wherein the dC/dT values are measured in a single dose human pharmacokinetic study over the time period between 0 and 4 hours after administration.

2. An osmotic device comprising a core surrounded by a semipermeable membrane having an exit means there through wherein: a) the core comprises a mixture of (i) a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, (ii) an osmotically active component and (iii) at least one other excipient, b) the osmotic device further comprises an immediate release overcoat layer comprising the drug, c) the osmotic device comprises a total of 50 mg to 500 mg of the drug, and at least 50% of the total drug is provided in the core, and d) the osmotic device provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT provided by the same quantity of an immediate release form of the drug, wherein the dC/dT values are measured in a single dose human pharmacokinetic study over the time period between administration and Tmax of the immediate release form.

3. An osmotic device comprising a core surrounded by a semipermeable membrane having an exit means there through wherein: a) the core comprises a mixture of (i) a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, (ii) an osmotically active component and (iii) at least one other excipient, b) the osmotic device further comprises an immediate release overcoat layer comprising the drug, c) the osmotic device comprises a total of 50 mg to 500 mg of the drug, and at least 50% of the total drug is provided in the core, and d) the osmotic device provides a mean change in amantadine plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT provided by the same quantity of an immediate release form of the drug, wherein the dC/dT of the osmotic device is measured in a single dose human pharmacokinetic study over the time period between 2 hours and 4 hours after administration and the dC/dT provided by the same quantity of the drug in an immediate release form is measured in a single dose human pharmacokinetic study over the time period between administration and Tmax of the immediate release form.

4. The osmotic device of any of claims 1 to 3, wherein the osmotic device comprises a total of 100 mg to 500 mg of the drug.

5. The osmotic device of any of claims 1 to 3, wherein the osmotic device comprises a total of 200 mg to 500 mg of the drug.

6. The osmotic device of any of claims 1 to 3, wherein at least 75% of the drug is provided in the core.

7. The osmotic device of any of claims 1 to 3, wherein at least 90% of the drug is provided in the core.

8. The osmotic device of any of claims 1 to 3, wherein the osmotic device provides a dC/dT that is less than 50% of the dC/dT provided by the same quantity of the drug in an immediate release form.

9. The osmotic device of any of claims 1 to 3, wherein the osmotic device provides a dC/dT that is less than 40% of the dC/dT provided by the same quantity of the drug in an immediate release form.

10. The osmotic device of any of claims 1 to 3, wherein the extent of drug bioavailability is maintained.

11. The osmotic device of any of claims 1 to 3, wherein the osmotic device provides a shift in amantadine Tmax of 2 hours to 16 hours relative to an immediate release form of amantadine, wherein the Tmax is measured in a single dose human pharmacokinetic study.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Farmers Insurance
Dow
Chubb
Chinese Patent Office
Queensland Health
Merck
Citi
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.